- Home
- CAN vs FULC Comparison
CAN vs FULC Comparison
Compare CAN & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAN
- FULC
- Stock Information
- Founded
- CAN 2013
- FULC 2015
- Country
- CAN Singapore
- FULC United States
- Employees
- CAN N/A
- FULC N/A
- Industry
- CAN Semiconductors
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- CAN Technology
- FULC Health Care
- Exchange
- CAN Nasdaq
- FULC Nasdaq
- Market Cap
- CAN 330.5M
- FULC 372.2M
- IPO Year
- CAN 2019
- FULC 2019
- Fundamental
- Price
- CAN $0.81
- FULC $7.32
- Analyst Decision
- CAN Strong Buy
- FULC Buy
- Analyst Count
- CAN 6
- FULC 8
- Target Price
- CAN $2.50
- FULC $7.13
- AVG Volume (30 Days)
- CAN 25.3M
- FULC 398.4K
- Earning Date
- CAN 08-14-2025
- FULC 11-12-2025
- Dividend Yield
- CAN N/A
- FULC N/A
- EPS Growth
- CAN N/A
- FULC N/A
- EPS
- CAN N/A
- FULC N/A
- Revenue
- CAN $345,360,000.00
- FULC N/A
- Revenue This Year
- CAN $90.25
- FULC N/A
- Revenue Next Year
- CAN $42.94
- FULC N/A
- P/E Ratio
- CAN N/A
- FULC N/A
- Revenue Growth
- CAN 82.40
- FULC 2752.05
- 52 Week Low
- CAN $0.53
- FULC $2.32
- 52 Week High
- CAN $3.27
- FULC $8.50
- Technical
- Relative Strength Index (RSI)
- CAN 59.68
- FULC 57.81
- Support Level
- CAN $0.77
- FULC $6.69
- Resistance Level
- CAN $0.85
- FULC $7.50
- Average True Range (ATR)
- CAN 0.04
- FULC 0.41
- MACD
- CAN 0.01
- FULC 0.06
- Stochastic Oscillator
- CAN 77.32
- FULC 63.82
About CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.